: Immunotherapy and the Emerging Pipeline
Despite the success of immunotherapy in other cancers, osteosarcoma has proven resistant due to its "cold" tumor microenvironment.
In 2026, US research is focused on "turning up the heat" using Mifamurtide (Mepact), an immune stimulant that activates macrophages to attack cancer cells. While not yet universally reimbursed by all US insurers, it is increasingly used in combination with chemotherapy. Other emerging agents in the 2026 pipeline include OST-HER2, a therapeutic vaccine designed to trigger the immune system to recognize and destroy HER2-expressing bone cancer cells.
2 Views